BR112018074966A2 - anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor - Google Patents

anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor

Info

Publication number
BR112018074966A2
BR112018074966A2 BR112018074966-4A BR112018074966A BR112018074966A2 BR 112018074966 A2 BR112018074966 A2 BR 112018074966A2 BR 112018074966 A BR112018074966 A BR 112018074966A BR 112018074966 A2 BR112018074966 A2 BR 112018074966A2
Authority
BR
Brazil
Prior art keywords
spinal cord
cord injury
pain
gum
treat spinal
Prior art date
Application number
BR112018074966-4A
Other languages
English (en)
Inventor
Klaus Mueller Bernhard
B. Jacobson Peer
Original Assignee
AbbVie Deutschland GmbH & Co. KG
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Deutschland GmbH & Co. KG, Abbvie Inc. filed Critical AbbVie Deutschland GmbH & Co. KG
Publication of BR112018074966A2 publication Critical patent/BR112018074966A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

são revelados anticorpos anti-rgma e métodos para usar esses anticorpos para tratar lesão da medula espinhal, incluindo promover regeneração axonal, recuperação funcional ou ambas e para tratar dor, incluindo dor neuropática que surge a partir da lesão da medula espinhal.
BR112018074966-4A 2016-06-01 2017-05-31 anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor BR112018074966A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344233P 2016-06-01 2016-06-01
US62/344,233 2016-06-01
PCT/US2017/035183 WO2017210278A1 (en) 2016-06-01 2017-05-31 Anti-repulsive guidance molecule a (rgma) antagonistic antibodies for treating spinal cord injury and pain

Publications (1)

Publication Number Publication Date
BR112018074966A2 true BR112018074966A2 (pt) 2019-03-12

Family

ID=59078172

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074966-4A BR112018074966A2 (pt) 2016-06-01 2017-05-31 anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor

Country Status (10)

Country Link
US (3) US20170349653A1 (pt)
EP (1) EP3464372A1 (pt)
JP (2) JP2019517480A (pt)
CN (1) CN109496218A (pt)
AU (1) AU2017273522A1 (pt)
BR (1) BR112018074966A2 (pt)
CA (1) CA3025329A1 (pt)
MX (1) MX2018014920A (pt)
TW (1) TW201803900A (pt)
WO (1) WO2017210278A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020013238A1 (ja) * 2018-07-10 2020-01-16 田辺三菱製薬株式会社 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法
EP3824907A4 (en) 2018-07-19 2022-05-04 The University of Tokyo AGENT FOR THE TREATMENT OR PREVENTION OF HTLV-1 ASSOCIATED MYELOPATHY (HAM), AND METHOD OF TREATMENT OF HAM

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
DE69232706T2 (de) 1991-05-01 2002-11-28 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
PT885002E (pt) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materiais e métodos para aumento da internalização celular
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
NZ520392A (en) 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
JP4955185B2 (ja) 2000-06-29 2012-06-20 アボット・ラボラトリーズ 二重特異性抗体ならびに作製方法および使用方法
DE602004024041D1 (de) 2003-03-05 2009-12-24 Halozyme Inc Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005046723A1 (en) * 2003-11-06 2005-05-26 Icos Corporation Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin
CN101370525B (zh) 2005-08-19 2013-09-18 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2331448B1 (es) * 2008-06-25 2010-10-18 Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Complejos de albumina con acidos grasos monoinsaturados omega-9 para el tratamiento de lesiones medulares.
SG10202006762PA (en) * 2012-01-27 2020-08-28 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US20140212423A1 (en) * 2012-12-04 2014-07-31 Abbvie, Inc. Blood-brain barrier penetrating dual specific binding proteins

Also Published As

Publication number Publication date
AU2017273522A1 (en) 2018-12-06
US20170349653A1 (en) 2017-12-07
WO2017210278A1 (en) 2017-12-07
CN109496218A (zh) 2019-03-19
MX2018014920A (es) 2019-08-26
TW201803900A (zh) 2018-02-01
EP3464372A1 (en) 2019-04-10
US20200347123A1 (en) 2020-11-05
JP2022091967A (ja) 2022-06-21
CA3025329A1 (en) 2017-12-07
US20220025031A1 (en) 2022-01-27
JP2019517480A (ja) 2019-06-24

Similar Documents

Publication Publication Date Title
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
NZ734714A (en) Methods of purifying cannabinoids, compositions and kits thereof
EA201792649A1 (ru) Способы кондиционирования пациентов для t-клеточной терапии
DE112017000012A5 (de) Finger-bewegungsschiene, halterung hierfür sowie dieses umfassendes therapiegerät und betriebsverfahren
BR112017024929A2 (pt) conjugados de oligonucleotídeo-peptídeo
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112018004680A2 (pt) método de tratamento de distúrbios de desenvolvimento
BR112016018170A2 (pt) métodos para tratar doença de alzheimer
BR112016015399A2 (pt) método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
BR112012005860A2 (pt) peptídeos isolados do veneno de aranha, e usos dos mesmos
WO2016183532A8 (en) Bacteria engineered to treat a disease or disorder
CO2018004684A2 (es) Métodos para tratar la epilepsia
MX2020002762A (es) Composiciones y métodos para tratar una lesión cerebral.
MX2019005165A (es) Compuestos polimericos que liberan sulfuro de hidrogeno.
MX2017006609A (es) Aditivo de nanocristales de celulosa o nanofibrillas de celulosa modificadas de forma quimica.
AR102062A1 (es) Proceso para la separación mejorada de etilbenceno
MX2016004837A (es) Formulaciones de solventes hibridos para la remocion total de azufre organico y la remocion de gas acido total.
BR112018074966A2 (pt) anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor
BR112017002629A2 (pt) decoys de oligonucleotídeo para o tratamento de dor
GB2548238A (en) Additive of cellulose nanofibrils or nanocrystals and a second polymer
BR112015029304A2 (pt) processo integrado para tratamento de dissulfetos de dialquila
EA201891419A1 (ru) Пептид-олигонуклеотидные конъюгаты
BR112015023260A2 (pt) método de tratamento de grão com ozônio

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]